Meeting
2023 ASCO Annual Meeting
Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer.
Authors
James Dickerson
Stanford Hospital & Clinics, Stanford, CA
James Dickerson , Marcus Moen , Perry Nielsen Jr., Edward Tran , Wesley Suen , Jeremy D Goldhaber-Fiebert , Fernando Alarid-Escudero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Care Delivery and Regulatory Policy
Track
Care Delivery and Quality Care
Sub Track
Health and Regulatory Policy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1593)
DOI
10.1200/JCO.2023.41.16_suppl.1593
Abstract #
1593
Poster Bd #
187
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
The cost-effectiveness of bevacizumab in combination with paclitaxel in first-line treatment of patients with metastatic breast cancer.
First Author: A. J. Montero
Poster
2021 ASCO Annual Meeting
Real-world cost-effectiveness of pertuzumab (P) with trastuzumab + chemo (T+Chemo) in patients (pts) with metastatic breast cancer (MBC): A population-based retrospective cohort study by the Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) collaboration.
First Author: Wei Fang Dai
Poster
2018 Genitourinary Cancers Symposium
Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer.
First Author: Michal Sarfaty
Poster
2016 ASCO Annual Meeting
Bevacizumab (bev) for metastatic colorectal cancer (mCRC): A global cost-effectiveness analysis.
First Author: Daniel A. Goldstein